Amphastar Pharmaceuticals Inc Quick Ratio (AMPH) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)

Amphastar Pharmaceuticals Inc 's Quick Ratio

AMPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.7 below Amphastar Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 376 other companies have achieved higher Quick Ratio than Amphastar Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1184 to 2148.

Explain Quick Ratio?
How much Cash & cash equivalents AMPH´s has?
What are AMPH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMPH Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 170.31 % -17.37 % -8.98 % 29.07 % -24.1 %
Y / Y Cash & cash equivalent Change 41.87 % 23.03 % 27.33 % 10.18 % -7.04 %
Quick Ratio MRQ 0.7 1.79 1.8 1.36 1.33
AMPH's Total Ranking # 2148 # 1184 # 467 # 1308 # 1230
Seq. Current Liabilities Change 189.92 % 4 % -22.94 % 16.34 % -11.38 %
Seq. Cash & cash equivalent Change 12.83 % 3.21 % 2.37 % 19 % -2.15 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 377
Healthcare Sector # 693
Overall Market # 2148


Quick Ratio Statistics
High Average Low
1.94 1.18 0.63
(Jun 30 2017)   (Jun 30 2018)




Financial Statements
Amphastar Pharmaceuticals Inc 's Current Liabilities $ 477 Millions Visit AMPH's Balance sheet
Amphastar Pharmaceuticals Inc 's Cash & cash equivalent $ 332 Millions Visit AMPH's Balance sheet
Source of AMPH's Sales Visit AMPH's Sales by Geography


Cumulative Amphastar Pharmaceuticals Inc 's Quick Ratio

AMPH's Quick Ratio for the trailling 12 Months

AMPH Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 41.86 % -7.85 % -9.94 % -13.48 % -27.06 %
Y / Y Cash & cash equivalent TTM Growth 25.26 % 12.84 % 1.62 % -7.57 % -14.03 %
Quick Ratio TTM 1.18 1.55 1.4 1.29 1.34
Total Ranking TTM # 3976 # 3075 # 1619 # 3114 # 3075
Seq. Current Liabilities TTM Growth 42.66 % -4.68 % -2.07 % 6.53 % -7.33 %
Seq. Cash & cash equivalent TTM Growth 8.97 % 5.31 % 6.27 % 2.71 % -1.83 %

Quick ratio ranking by company, industry and sector >> Back to AMPH Financial Strength Comparisons >> Go to Compare AMPH Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $476.85 millions, cumulative Quick Ratio decreased to 1.18 above the AMPH average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 434 other companies have achieved higher Quick Ratio than Amphastar Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3075 to 3976.

Explain Quick Ratio?
How much Cash & cash equivalents AMPH´s has?
What are AMPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 435
Healthcare Sector # 893
Within the Market # 3976


trailing twelve months Quick Ratio Statistics
High Average Low
1.83 1.17 0.77
(Mar 31 2023)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions
Revium Rx.  1.55 $ 1.506  Millions$ 0.971  Millions
Liquidia Corporation  1.50 $ 284.181  Millions$ 189.298  Millions
Greenwich Lifesciences Inc   1.50 $ 8.876  Millions$ 5.923  Millions
Arcutis Biotherapeutics Inc   1.49 $ 238.552  Millions$ 160.340  Millions
Mirum Pharmaceuticals Inc   1.48 $ 330.728  Millions$ 222.788  Millions
Regeneron Pharmaceuticals Inc   1.45 $ 7,994.600  Millions$ 5,530.600  Millions
Imunon Inc   1.44 $ 6.900  Millions$ 4.779  Millions
Zai Lab Limited  1.44 $ 617.522  Millions$ 428.584  Millions
Mannkind Corporation  1.44 $ 205.271  Millions$ 142.898  Millions
Kyntra Bio Inc   1.41 $ 50.644  Millions$ 36.040  Millions
Medicus Pharma Ltd   1.40 $ 15.174  Millions$ 10.841  Millions
Aurinia Pharmaceuticals Inc   1.39 $ 179.732  Millions$ 129.084  Millions
Omeros Corporation  1.39 $ 131.953  Millions$ 94.963  Millions

Date modified: 2026-09-26T07:10:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.